Your browser doesn't support javascript.
loading
The Therapeutic Effects of a Traditional Chinese Medicine Formula Wuzi Yanzong Pill for the Treatment of Oligoasthenozoospermia: A Meta-Analysis of Randomized Controlled Trials.
Zhao, Ming Peng; Shi, Xiao; Kong, Grace Wing Shan; Wang, Chi Chiu; Wu, Justin Che Yuen; Lin, Zhi Xiu; Li, Tin Chiu; Chan, David Yiu Leung.
Afiliación
  • Zhao MP; Department of Obstetrics and Gynecology, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
  • Shi X; Department of Obstetrics and Gynecology, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
  • Kong GWS; Department of Obstetrics and Gynecology, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
  • Wang CC; Department of Obstetrics and Gynecology, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
  • Wu JCY; Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
  • Lin ZX; School of Chinese Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
  • Li TC; Hong Kong Institute of Integrative Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
  • Chan DYL; Department of Obstetrics and Gynecology, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
Article en En | MEDLINE | ID: mdl-29576794
Oligoasthenozoospermia is a crucial factor in male infertility. Wuzi Yanzong (WZYZ) pill is a popular traditional Chinese medicine (TCM) formula which has been used for male infertility treatment for years. However, its effects on semen quality remain controversial. We conducted a preregistered meta-analysis to assess the effect of WZYZ pill for the therapeutic effects on oligoasthenozoospermia. Five randomized controlled trials including 960 participants were selected from databases of domains in North-East Asian regions, PubMed, Embase, and Cochrane Library. WZYZ pill group yielded a greater mean increment on sperm concentration (5 trials: MD 5.99, 95% CI 2.12-9.85, P = 0.002), sperm motility (5 trials: MD 4.57, 95% CI 0.47-8.68, P = 0.03), sperm morphology (2 trials: MD -1.93, 95% CI -4.87-1.01, P = 0.20), activity of acrosomal enzyme (2 trials: MD 28.27, 95% CI 12.41-44.14, P < 0.01), volume of semen (2 trials: MD 0.56, 95% CI 0.21-0.91, P = 0.002), and a decrement of sperm DNA fragmentation index (2 trials: MD -3.82, 95% CI -6.45--1.19, P = 0.004). However, qualities of selected studies were generally unsatisfactory, and there was inherent heterogeneity among some of the outcomes. Despite these limitations, the WZYZ pill improved sperm quality by improving several semen parameters and decreasing DNA damage in oligoasthenozoospermia patients.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Systematic_reviews Idioma: En Revista: Evid Based Complement Alternat Med Año: 2018 Tipo del documento: Article País de afiliación: Hong Kong Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Systematic_reviews Idioma: En Revista: Evid Based Complement Alternat Med Año: 2018 Tipo del documento: Article País de afiliación: Hong Kong Pais de publicación: Estados Unidos